home · filing · 0000950170-23-011487
8-K filed April 3, 2023, 7:59 PM ET
ticker HRTX
CIK 0000818033
leadership
confidence high
sentiment neutral
materiality 0.65
Heron Therapeutics appoints Craig Collard as CEO, Adam Morgan as Chairman
HERON THERAPEUTICS, INC. /DE/
Craig Collard appointed CEO effective April 3, 2023, succeeding Barry Quart who stepped down.
Adam Morgan elected Chairman of the Board; CEO and Chairman roles are now separate.
Collard's compensation: $650,000 base salary, 75% target bonus, equity grants including 3M stock options and up to 4.25M performance-based options.
Board reduced to seven members as part of governance changes.
Departure of Barry Quart not due to any disagreement; he may assist with transition under a consulting agreement.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2023-04-03
Filed April 3, 2023, 7:59 PM ET
appointed Craig Collard as the Company’s Chief Executive Officer, effective April 3, 2023
Effective 2023-04-03
Successor Craig Collard
Filed April 3, 2023, 7:59 PM ET
Mr. Collard succeeds Barry Quart, who will cease to serve as the Company’s Chairman, Chief Executive Officer and a director as of the Effective Date
Effective 2023-04-03
Filed April 3, 2023, 7:59 PM ET
appointed current director Adam Morgan to serve as Chairman of the Board, effective as of the Effective Date
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Craig Collard was appointed as Chief Executive Officer at HERON THERAPEUTICS, INC. /DE/.
Action appointed
Role Chief Executive Officer
Exact text from the filing
appointed Craig Collard as the Company’s Chief Executive Officer, effective April 3, 2023
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Barry Quart departed as Chief Executive Officer at HERON THERAPEUTICS, INC. /DE/.
Action ceased
Role Chief Executive Officer
Exact text from the filing
Mr. Collard succeeds Barry Quart, who will cease to serve as the Company’s Chairman, Chief Executive Officer and a director as of the Effective Date
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Adam Morgan was appointed as Chairman of the Board at HERON THERAPEUTICS, INC. /DE/.
Action appointed
Role Chairman of the Board
Exact text from the filing
appointed current director Adam Morgan to serve as Chairman of the Board, effective as of the Effective Date
View on SEC.gov
Source: SEC EDGAR
accession 0000950170-23-011487
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.